Literature DB >> 9626865

Quantitative MRI of the brain in children with sickle cell disease reveals abnormalities unseen by conventional MRI.

R G Steen1, W E Reddick, R K Mulhern, J W Langston, R J Ogg, A A Bieberich, P B Kingsley, W C Wang.   

Abstract

Conventional MRI (cMRI) has shown that brain abnormalities without clinical stroke can manifest in patients with sickle cell disease (SCD). We used quantitative MRI (qMRI) and psychometric testing to determine whether brain abnormalities can also be present in patients with SCD who appear normal on cMRI. Patients 4 years of age and older with no clinical evidence of stroke were stratified by cMRI as normal (n = 17) or abnormal (n = 13). Spin-lattice relaxation time (T1) of gray and white matter structures was measured by the precise and accurate inversion recovery (PAIR) qMRI method. Patient cognitive ability was assessed with a standard psychometric instrument (WISC-III or WISC-R). In all 30 patients with SCD, qMRI T1 was lower than in 24 age- and race-matched controls, in cortical gray matter (P < .0006) and caudate (P < .0009), as well as in the ratio of gray-to-white matter T1 (P < .008). In the 17 patients who were shown to be normal by cMRI, qMRI T1 was still lower than in controls, in both cortical gray matter (P < .02) and caudate (P < .004). Histograms of voxel T1 show that the proportion of voxels with T1 values intermediate between gray and white matter (ie, consistent with encephalomalacia) was 9% higher than controls in patients shown to be normal by cMRI (P < .05) and 15% higher than controls in patients shown to be abnormal by cMRI (P < .0005). The full scale intelligence quotient (FSIQ) of all patients with SCD was 75, compared to the FSIQ of 88 in a historical control group of patient siblings (P < .001). The FSIQ of patients shown to be normal by cMRI was 79, significantly lower than the FSIQ of patient siblings (P < .04). The FSIQ of 71 in patients shown to be abnormal by cMRI was significantly lower than both the patient siblings (P < .005) and the patients shown to be normal by cMRI (P < .04). Patients shown to be abnormal by cMRI scored lower than patients shown to be normal by cMRI, specifically on the subtests of vocabulary (P = .003) and information (P = .03). Cognitive impairment is thus significant, even in patients with SCD who were shown to be normal by cMRI, suggesting that cMRI may be insensitive to subtle neurologic damage that can be detected by qMRI. Because cognitive impairment can occur in children normal by cMRI, our findings imply that prophylactic therapy may be needed earlier in the course of SCD to mitigate neurologic damage.

Entities:  

Mesh:

Year:  1998        PMID: 9626865     DOI: 10.1002/jmri.1880080304

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  11 in total

1.  Parent education and biologic factors influence on cognition in sickle cell anemia.

Authors:  Allison A King; John J Strouse; Mark J Rodeghier; Bruce E Compas; James F Casella; Robert C McKinstry; Michael J Noetzel; Charles T Quinn; Rebecca Ichord; Michael M Dowling; J Philip Miller; Michael R Debaun
Journal:  Am J Hematol       Date:  2014-02       Impact factor: 10.047

Review 2.  Neuropsychological aspects of pediatric sickle cell disease.

Authors:  M C Kral; R T Brown; G W Hynd
Journal:  Neuropsychol Rev       Date:  2001-12       Impact factor: 7.444

Review 3.  Sickle Cell Disease and Stroke: Diagnosis and Management.

Authors:  Courtney Lawrence; Jennifer Webb
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

Review 4.  Novel insights in the management of sickle cell disease in childhood.

Authors:  Lorenzo Iughetti; Elena Bigi; Donatella Venturelli
Journal:  World J Clin Pediatr       Date:  2016-02-08

5.  Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities.

Authors:  R G Steen; J S Taylor; J W Langston; J O Glass; V R Brewer; W E Reddick; R Mages; E K Pivnick
Journal:  AJNR Am J Neuroradiol       Date:  2001-05       Impact factor: 3.825

Review 6.  Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia.

Authors:  Michael R DeBaun; F Daniel Armstrong; Robert C McKinstry; Russell E Ware; Elliot Vichinsky; Fenella J Kirkham
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

7.  Neuroimaging abnormalities in adults with sickle cell anemia: associations with cognition.

Authors:  R Scott Mackin; Philip Insel; Diana Truran; Elliot P Vichinsky; Lynne D Neumayr; F D Armstrong; Jeffrey I Gold; Karen Kesler; Joseph Brewer; Michael W Weiner
Journal:  Neurology       Date:  2014-02-12       Impact factor: 9.910

8.  Do chronic pain and comorbidities affect brain function in sickle cell patients? A systematic review of neuroimaging and treatment approaches.

Authors:  Joyce T Da Silva; Janelle E Letzen; Jennifer A Haythornthwaite; Patrick H Finan; Claudia M Campbell; David A Seminowicz
Journal:  Pain       Date:  2019-09       Impact factor: 7.926

Review 9.  Stroke and presence of patent foramen ovale in sickle cell disease.

Authors:  Constantina Aggeli; Kali Polytarchou; Yannis Dimitroglou; Dimitrios Patsourakos; Sophia Delicou; Sophia Vassilopoulou; Eleftherios Tsiamis; Kostas Tsioufis
Journal:  J Thromb Thrombolysis       Date:  2021-02-26       Impact factor: 2.300

10.  Neuropsychological assessment, neuroimaging, and neuropsychiatric evaluation in pediatric and adult patients with sickle cell disease (SCD).

Authors:  Christopher L Edwards; Renee Dunn Raynor; Miriam Feliu; Camela McDougald; Stephanie Johnson; Donald Schmechel; Mary Wood; Gary G Bennett; Patrick Saurona; Melanie Bonner; Chante' Wellington; Laura M DeCastro; Elaine Whitworth; Mary Abrams; Patrick Logue; Lekisha Edwards; Salutario Martinez; Keith E Whitfield
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.